ClinicalTrials.gg
RecruitingNCT04343430AHF-CODE-PUpdated Jun 5, 2023

Acute Heart Failure With Preserved Ejection Fraction - COngestion Discharge Evaluation

An interventional study of Clinical examination centered on congestion and Cardio-pulmonary, peritoneal, jugular and renal Doppler ultrasounds and liver elastography in Acute Heart Failure, sponsored by Central Hospital, Nancy, France. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-06-05.

Sponsored by Central Hospital, Nancy, France · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Aug 2020; still recruiting 6 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
170
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Heart Failure by Central Hospital, Nancy, France — 9 open to participants now, 10 under way, 1 of them phase 3. Heart Failure · Central Hospital, Nancy, France.

Planned enrollment
4th of 13
170 · median 103
Started
2020
with 2 others
No phase
12 of 19
8 open now
Registered
8th of 19
by date

Among the 19 studies in Heart Failure by Central Hospital, Nancy, France, this one is the 4th largest by planned enrollment of the 13 interventional ones that give a count, is one of 3 that started in 2020, is one of 12 with no phase, and was the 8th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

9 of the 19 studies in Heart Failure by Central Hospital, Nancy, France are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Heart Failure by Central Hospital, Nancy, France, or all of them as a file.
02

Study summary

The AHF-CODE preserved study is a prospective, non-randomized, monocenter study performed in patients with heart failure with preserved ejection fraction admitted for worsening heart failure.

The main objective of the AHF-CODE preserved study is to identify congestion markers (clinical, biological and ultrasound) at the end of hospitalization for acute heart failure that are associated with the risk of all cause death or rehospitalization for acute heart failure within 3 months of hospital discharge.

03

Conditions studied

  • Acute Heart Failure

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients hospitalised for acute heart failure.
  • Patient with preserved (FE ≥ 50%).
  • Patients considered clinically discharging from hospitalisation for acute heart failure.
  • Age ≥18 years
  • Patients having received complete information regarding the study design and having signed their form.
  • Patient affiliated to or beneficiary of a social security scheme.

Exclusion criteria

Exclusion Criteria:

  • Comorbidity for which the is ≤ 3 months
  • Dialysis patient (peritoneal dialysis or hemodialysis) or patients with \<15 ml/min/m² at inclusion.
  • History of lobectomy or pneumonectomy lung surgery
  • Severe pulmonary or pleural pathology preventing reliable acquisition of lung ultrasound images: severe emphysema, chronic pleurisy, pulmonary fibrosis, etc.
  • Pregnant woman, parturient or nursing mother
  • Adult person subject to a legal protection measure (guardianship, curatorship, safeguard of justice)
  • Adult person who is unable to give consent
  • Person deprived of liberty by a judicial or administrative decision,
  • Person subject to psychiatric care pursuant to Articles L. 3212-1 and L. 3213-1 of the Public Health Code.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
170 participants (estimated)

Study arms

  • Other
    Patients hospitalized for acute heart failure

    Patients hospitalized for acute heart failure will undergo the following evaluations: * Clinical examination centered on congestion * Cardiopulmonary , peritoneal , jugular and renal venous Doppler ultrasounds * Blood sample retrieved for biological assessment and biobanking * Telephone interview

    Procedure: Clinical examination centered on congestion · Procedure: Cardio-pulmonary, peritoneal, jugular and renal Doppler ultrasounds and liver elastography · Procedure: Biological: Blood sample retrieved for biological assessment and biobanking · Procedure: Telephone interview · Behavioral: Kansas City Cardiomyopathy Questionnaire (KCCQ)

Interventions

  • ProcedureClinical examination centered on congestion

    Clinical examination centered on congestion (ASCEND, NYHA and Ambrosy Score) will be performed before discharge from hospital

  • ProcedureCardio-pulmonary, peritoneal, jugular and renal Doppler ultrasounds and liver elastography

    Cardio-pulmonary, peritoneal, jugular and renal Doppler ultrasounds and liver elastography will be performed before discharge from hospital

  • ProcedureBiological: Blood sample retrieved for biological assessment and biobanking

    Blood sample collection will be performed before discharge from hospital

  • ProcedureTelephone interview

    Telephone interview will be performed at 3, 12 months and 24 months after discharge from Hospital

  • BehavioralKansas City Cardiomyopathy Questionnaire (KCCQ)

    Questionnaire centered on patient's quality of life at discharge and 3, 12 and 24 months after discharge

06

What researchers measure

Primary outcomes

  1. Rate of all-cause death

    composite endpoint : rate of all-cause death or re-hospitalisation for acute heart failure at 3 months after hospital discharge (with outcome 2 and 3)

    Time frame: 3 months after hospital discharge

  2. Rate of re-hospitalisation for acute heart failure

    composite endpoint : rate of all-cause death or re-hospitalisation for acute heart failure at 3 months after hospital discharge (with outcome 1 and 3)

    Time frame: 3 months after hospital discharge

  3. Rate of day-hospital or in-home IV diuretics injection for acute HF

    composite endpoint : rate of all-cause death or re-hospitalisation for acute heart failure at 3 months after hospital discharge (with outcome 2 and 3)

    Time frame: 3 months after hospital discharge

Secondary outcomes

  1. Rate of all-cause death

    composite endpoint : rate of all-cause death or re-hospitalisation for acute heart failure at 3,12 and 24 months after hospital discharge (with outcome 5)

    Time frame: 3, 12 and 24 months after hospital discharge

  2. Rate of re-hospitalisation for acute heart failure

    composite endpoint : rate of all-cause death or re-hospitalisation for acute heart failure at 3, 12 and 24 months after hospital discharge (with outcome 4)

    Time frame: 3, 12 and 24 months after hospital discharge

  3. rate of day-hospital or in home IV diuretics injection for acute HF

    Time frame: 3, 12 and 24 months after hospital discharge

  4. Rate of all-cause death

    Rate of all-cause death at 3, 12 and 24 months after hospital discharge

    Time frame: 3, 12 and 24 months after hospital discharge

  5. Rate of hospitalisation for acute heart failure

    Rate of hospitalisation for acute heart Failure at 3, 12 and 24 months after hospital discharge

    Time frame: 3, 12 and 24 months after hospital discharge

  6. Rate of all-cause death

    composite endpoint : rate of all-cause death or re-hospitalisation for acute heart failure at 3 months after hospital discharge (with outcome 10)

    Time frame: 3, 12 and 24 months after hospital discharge

  7. Rate of hospitalisation for acute heart failure

    composite endpoint : rate of all-cause death or re-hospitalisation for acute heart failure at 3 months after hospital discharge (with outcome 9)

    Time frame: 3, 12 and 24 months after hospital discharge

  8. Rate of death from all causes

    composite endpoint : rate of all-cause death or re-hospitalisation for acute heart failure at 3, 12 and 24 months after hospital discharge (with outcome 12)

    Time frame: 3, 12 and 24 months after hospital discharge

  9. Rate of hospitalisation for acute heart failure

    composite endpoint : rate of all-cause death or re-hospitalisation for acute heart failure at 3, 12 and 24 months after hospital discharge (with outcome 11)

    Time frame: 3, 12 and 24 months after hospital discharge

  10. NYHA (New York Heart Association) class

    Time frame: 3, 12 and 24 months after hospital discharge

  11. Natriuretic peptides

    BNP or Nt-Pro BNP

    Time frame: At inclusion

  12. Renal function assessed by glomerular filtration rate

    Time frame: At inclusion

  13. Plasma volume

    Calculated from haemoglobin and haematocrit value

    Time frame: At inclusion

  14. Blood potassium

    Time frame: At inclusion

  15. Liver elastography value

    Measured with Fibroscan®

    Time frame: At inclusion

  16. Quality of life assessed by Kansas City Cardiomyopathy Questionnaire

    Assessed by Kansas City Cardiomyopathy Questionnaire (KCCQ)

    Time frame: At inclusion and 3, 6 and 24 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2020 (actual). Primary completion is estimated for Aug 2026, 72 months after the start.

Of 1,119 non-industry interventional studies with no phase under Heart Failure, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's planned 72 months is above that.

Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 9, 2020
First posted
Apr 13, 2020
StartActual
Aug 29, 2020
Primary completionEst.
Aug 29, 2026
CompletionEst.
Aug 29, 2028
Last update
Jun 5, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 5, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04343430
Responsible party
Pr. Nicolas GIRERD (Acute Heart Failure With Preserved Ejection Fraction - COngestion Discharge Evaluation: Evaluation de la Congestion à la Sortie d'Hospitalisation Pour Insuffisance Cardiaque aiguë à Fraction d'éjection préservée, Central Hospital, Nancy, France) — Principal investigator
First posted
Apr 13, 2020
Start date
Aug 29, 2020
Primary completion
Aug 29, 2026 (estimated)
Completion
Aug 29, 2028 (estimated)
Last update
Jun 5, 2023

Study contacts

Nicolas GIRERD, MD,PhD
Contact
n.girerd@chru-nancy.fr
+ 33 3 83 15 73 22 ext. + 33 3

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion